CA3171349A1 - N-cyanopyrrolidines with activity as usp30 inhibitors - Google Patents

N-cyanopyrrolidines with activity as usp30 inhibitors

Info

Publication number
CA3171349A1
CA3171349A1 CA3171349A CA3171349A CA3171349A1 CA 3171349 A1 CA3171349 A1 CA 3171349A1 CA 3171349 A CA3171349 A CA 3171349A CA 3171349 A CA3171349 A CA 3171349A CA 3171349 A1 CA3171349 A1 CA 3171349A1
Authority
CA
Canada
Prior art keywords
disease
compound
fibrosis
tautomer
deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171349A
Other languages
English (en)
French (fr)
Inventor
Christopher Andrew Luckhurst
Mark Ian Kemp
Paul William Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2005250.2A external-priority patent/GB202005250D0/en
Priority claimed from GBGB2016607.0A external-priority patent/GB202016607D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of CA3171349A1 publication Critical patent/CA3171349A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3171349A 2020-04-08 2021-04-07 N-cyanopyrrolidines with activity as usp30 inhibitors Pending CA3171349A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2005250.2 2020-04-08
GBGB2005250.2A GB202005250D0 (en) 2020-04-08 2020-04-08 Novel compounds
GB2016607.0 2020-10-20
GBGB2016607.0A GB202016607D0 (en) 2020-10-20 2020-10-20 Novel Compounds
PCT/EP2021/059032 WO2021204856A1 (en) 2020-04-08 2021-04-07 N-cyanopyrrolidines with activity as usp30 inhibitors

Publications (1)

Publication Number Publication Date
CA3171349A1 true CA3171349A1 (en) 2021-10-14

Family

ID=75441909

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171349A Pending CA3171349A1 (en) 2020-04-08 2021-04-07 N-cyanopyrrolidines with activity as usp30 inhibitors

Country Status (13)

Country Link
US (1) US20230119013A1 (enExample)
EP (1) EP4132925A1 (enExample)
JP (1) JP2023520727A (enExample)
KR (1) KR20230006487A (enExample)
CN (1) CN115461340A (enExample)
AU (1) AU2021253617A1 (enExample)
BR (1) BR112022020058A2 (enExample)
CA (1) CA3171349A1 (enExample)
CO (1) CO2022014134A2 (enExample)
IL (1) IL296998A (enExample)
MX (1) MX2022012578A (enExample)
WO (1) WO2021204856A1 (enExample)
ZA (1) ZA202212137B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245186A1 (en) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
RS67140B1 (sr) 2020-06-08 2025-09-30 Mission Therapeutics Ltd 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
CN117887844B (zh) * 2023-12-28 2024-08-23 中山大学附属第一医院 Usp20在肝癌放疗增敏中的应用
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds
GB202500610D0 (en) 2025-01-16 2025-03-05 Mission Therapeutics Ltd Novel compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JP2003530384A (ja) 2000-04-06 2003-10-14 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害薬
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
UY31770A1 (es) 2008-04-18 2009-09-30 Inhibidores de catepsina c
UY31771A1 (es) 2008-04-18 2009-09-30 Inhibidores de catepsina c
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
JP6612751B2 (ja) 2013-07-31 2019-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
US20170095457A1 (en) 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
LT3277677T (lt) * 2015-03-30 2021-05-25 Mission Therapeutics Limited 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) * 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
AU2018346597B2 (en) * 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
EP3837262B1 (en) * 2018-08-14 2026-06-17 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
CO2022014134A2 (es) 2022-10-31
EP4132925A1 (en) 2023-02-15
CN115461340A (zh) 2022-12-09
WO2021204856A1 (en) 2021-10-14
IL296998A (en) 2022-12-01
KR20230006487A (ko) 2023-01-10
AU2021253617A1 (en) 2022-12-01
MX2022012578A (es) 2022-11-07
JP2023520727A (ja) 2023-05-18
US20230119013A1 (en) 2023-04-20
ZA202212137B (en) 2024-07-31
BR112022020058A2 (pt) 2022-11-22

Similar Documents

Publication Publication Date Title
EP4025573B9 (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
EP4157834B1 (en) N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
WO2020212350A1 (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
EP4161929B1 (en) 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
AU2021253617A1 (en) N-cyanopyrrolidines with activity as USP30 inhibitors
WO2020212351A1 (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
JP7796047B2 (ja) Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
WO2022084479A1 (en) N-cyanopyrrolidines with activity as usp30 inhibitors
RU2848457C1 (ru) N-Цианопирролидины с активностью ингибиторов USP30
RU2822680C1 (ru) Замещенные цианопирролидины, обладающие активностью ингибиторов USP30
HK40068349A (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250922

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260519

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260806